Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Biomay
Biomay
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Manufacturing
Biomay announces expansion of GMP-facilities to offer mRNA manufacturing and aseptic filling services
Biomay expanded its biomanufacturing facility in central Vienna by adding cleanrooms, laboratories and warehouse premises in the Vienna Competence Center building
Finance
Biomay manufacturing facility continues on schedule
The building itself is planned to be completed in September 2021, followed by manufacturing equipment and process utilities, aimed to be installed by Q3 2021
Manufacturing
BIA Separations and Biomay collaborate on production and purification of large DNA plasmids
The collaboration enables high yield, high purity supercoiled plasmid DNA manufacture for therapeutic application
Subscribe now